InMed Pharmaceuticals Inc logo

IN - InMed Pharmaceuticals Inc Share Price

C$6.92 -0.1  -1.8%

Last Trade - 10/08/20

Micro Cap
Market Cap £21.1m
Enterprise Value £15.6m
Revenue £n/a
Position in Universe 1050th / 2675
Unlock IN Revenue
Relative Strength (%)
1m -3.91%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -52.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 March 2020, InMed Pharmaceuticals Inc revenues was not reported. Net loss increased 6% to C$9.5M. Higher net loss reflects Accounting and legal increase of 68% to C$683K (expense), Other Income (Loss) Interest income decrease of 51% to C$166K (income), Salaries and benefits increase of 15% to C$1.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$1.73 to -C$1.83.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IN Revenue Unlock IN Revenue

Net Income

IN Net Income Unlock IN Revenue

Normalised EPS

IN Normalised EPS Unlock IN Revenue

PE Ratio Range

IN PE Ratio Range Unlock IN Revenue

Dividend Yield Range

IN Dividend Yield Range Unlock IN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IN EPS Forecasts Unlock IN Revenue
Profile Summary

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Last Annual June 30th, 2019
Last Interim March 31st, 2020
Incorporated May 19, 1981
Public Since March 26, 2018
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Toronto Stock Exchange
Shares in Issue 5,220,707
Free Float (0.0%)
Eligible for
IN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IN
Upcoming Events for IN
Frequently Asked Questions for InMed Pharmaceuticals Inc
What is the InMed Pharmaceuticals Inc share price?

As of 10/08/20, shares in InMed Pharmaceuticals Inc are trading at C$6.92, giving the company a market capitalisation of £21.1m. This share price information is delayed by 15 minutes.

How has the InMed Pharmaceuticals Inc share price performed this year?

Shares in InMed Pharmaceuticals Inc are currently trading at C$6.92 and the price has moved by -19.38% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the InMed Pharmaceuticals Inc price has moved by -20.54% over the past year.

What are the analyst and broker recommendations for InMed Pharmaceuticals Inc?

Of the analysts with advisory recommendations for InMed Pharmaceuticals Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for InMed Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will InMed Pharmaceuticals Inc next release its financial results?

InMed Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the InMed Pharmaceuticals Inc dividend yield?

InMed Pharmaceuticals Inc does not currently pay a dividend.

Does InMed Pharmaceuticals Inc pay a dividend?

InMed Pharmaceuticals Inc does not currently pay a dividend.

When does InMed Pharmaceuticals Inc next pay dividends?

InMed Pharmaceuticals Inc does not currently pay a dividend.

How do I buy InMed Pharmaceuticals Inc shares?

To buy shares in InMed Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of InMed Pharmaceuticals Inc?

Shares in InMed Pharmaceuticals Inc are currently trading at C$6.92, giving the company a market capitalisation of £21.1m.

Where are InMed Pharmaceuticals Inc shares listed? Where are InMed Pharmaceuticals Inc shares listed?

Here are the trading details for InMed Pharmaceuticals Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: IN
What kind of share is InMed Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, InMed Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a InMed Pharmaceuticals Inc share price forecast 2020?

Shares in InMed Pharmaceuticals Inc are currently priced at C$6.92. At that level they are trading at 0.111% discount to the analyst consensus target price of 0.00.

Analysts covering InMed Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.805 for the next financial year.

How can I tell whether the InMed Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InMed Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -30.73%. At the current price of C$6.92, shares in InMed Pharmaceuticals Inc are trading at -18.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the InMed Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for InMed Pharmaceuticals Inc.

Who are the key directors of InMed Pharmaceuticals Inc?

InMed Pharmaceuticals Inc's management team is headed by:

Abo Mohammed - OTH
Adam Cutler - DRC
William Garner - CHM
Eric Adams - PRE
Andrew Hull - DRC
Alexandra Mancini - SVP
Jeffrey Charpentier - CFO
Martin Bott - DRC
Josh Blacher - OTH
Catherine Sazdanoff - DRC
Bruce Colwill - CFO
Who are the major shareholders of InMed Pharmaceuticals Inc?

Here are the top five shareholders of InMed Pharmaceuticals Inc based on the size of their shareholding:

Adams (Eric A.) Individual Investor
Percentage owned: 0.59% (31.0k shares)
Hull (Andrew Harold) Individual Investor
Percentage owned: 0.36% (18.9k shares)
Vitreo Gestão de Recursos Ltda. Investment Advisor
Percentage owned: 0.09% (4.66k shares)
Vitreo Canabidiol FI Acoes Investimento Mutual Fund
Percentage owned: 0.09% (4.66k shares)
Evolve Funds Group Inc Investment Advisor
Percentage owned: 0.04% (64.4k shares)
Similar to IN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.